IKT vs TENX
IKT: A pre-revenue biotech company developing IKT-001, a novel therapeutic targeting pulmonary arterial hypertension, currently in Phase 3 clinical trials with no approved products or operating revenue. TENX: Tenax Therapeutics is a clinical-stage biotechnology company developing specialized therapies for pulmonary hypertension and other cardiopulmonary conditions.
Side-by-side fundamentals
| Metric | IKT | TENX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.35 | $16.19 | |
| Market cap as of 2026-08-03 | $310M | $429M | |
| Net margin as of 2026-08-03 | -5981.3% | -10115.8% | IKT higher |
| Gross margin as of 2026-08-03 | n/a | +100.0% | |
| Operating margin as of 2026-08-03 | -6253.1% | -10390.5% | IKT higher |
| ROE as of 2026-08-03 | -57.1% | -56.3% | TENX higher |
| ROA as of 2026-08-03 | -52.8% | -53.1% | IKT higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-03 | n/a | -82.9% | |
| Beta as of 2026-08-03 | 0.97 | 0.96 | |
| 1-year return as of 2026-07-27 close | +32.8% | +167.6% | TENX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.